Pomerantz Roger J
Center for Human Virology and Biodefense, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Arch Immunol Ther Exp (Warsz). 2004 Sep-Oct;52(5):297-306.
Over the last 18 years of study in one of our laboratories, we have observed the development of residual disease and latent reservoirs as major problems in the long-term therapy of HIV-1-infected individuals on highly active antiretroviral therapy (HAART). It was shown in the early 1990 's that HAART, as it is presently configured, is unlikely to lead to viral eradication due to several mechanisms of viral persistence. The two general mechanisms involved with persistence during HAART include low-level residual, cryptic replication and proviral latently-infected cells. As such, these are key areas of potential studyfor depletion and, hopefully in the future, eradication of residual disease in patients on suppressive HAART. To deplete these residual disease mechanisms will require multipronged approaches. These will include induction of HIV-1 latent proviruses, suppression of residual viral replication and destruction of long-lived cellular sanctuaries, such astissue-bound macrophages.
在我们其中一个实验室过去18年的研究中,我们观察到残余疾病和潜伏储存库的形成是接受高效抗逆转录病毒疗法(HAART)的HIV-1感染个体长期治疗中的主要问题。在20世纪90年代早期就已表明,按照目前的配置,HAART由于多种病毒持续存在机制,不太可能导致病毒根除。HAART治疗期间病毒持续存在涉及的两个主要机制包括低水平残余、隐匿性复制以及前病毒潜伏感染细胞。因此,这些是在接受抑制性HAART治疗的患者中进行潜在研究以清除并有望在未来根除残余疾病的关键领域。要清除这些残余疾病机制需要采取多管齐下的方法。这些方法将包括诱导HIV-1潜伏前病毒、抑制残余病毒复制以及破坏长寿细胞庇护所,如组织驻留巨噬细胞。